Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
Keisuke Watanabe, … , Akseli Hemminki, Carl H. June
Keisuke Watanabe, … , Akseli Hemminki, Carl H. June
Published April 5, 2018
Citation Information: JCI Insight. 2018;3(7):e99573. https://doi.org/10.1172/jci.insight.99573.
View: Text | PDF
Research Article Therapeutics

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction. Mesothelin-redirected chimeric antigen receptor T cell (meso-CAR T cell) therapy has shown some efficacy in clinical trials but antitumor efficacy remains modest. We hypothesized that combined meso-CAR T cells with an oncolytic adenovirus expressing TNF-α and IL-2 (Ad5/3-E2F-D24-TNFa-IRES-IL2, or OAd-TNFa-IL2) would improve efficacy. OAd-TNFa-IL2 enhanced the antitumor efficacy of meso-CAR T cells in human-PDA-xenograft immunodeficient mice and efficacy was associated with robustly increased tumor-infiltrating lymphocytes (TILs), enhanced and prolonged T cell function. Mice treated with parental OAd combined with meso-CAR T developed tumor metastasis to the lungs even if primary tumors were controlled. However, no mice treated with combined OAd-TNFa-IL2 and meso-CAR T died of tumor metastasis. We also evaluated this approach in a syngeneic mouse tumor model by combining adenovirus expressing murine TNF-α and IL-2 (Ad-mTNFa-mIL2) and mouse CAR T cells. This approach induced significant tumor regression in mice engrafted with highly aggressive and immunosuppressive PDA tumors. Ad-mTNFa-mIL2 increased both CAR T cell and host T cell infiltration to the tumor and altered host tumor immune status with M1 polarization of macrophages and increased dendritic cell maturation. These findings indicate that combining cytokine-armed oncolytic adenovirus to enhance the efficacy of CAR T cell therapy is a promising approach to overcome the immunosuppressive TME for the treatment of PDA.

Authors

Keisuke Watanabe, Yanping Luo, Tong Da, Sonia Guedan, Marco Ruella, John Scholler, Brian Keith, Regina M. Young, Boris Engels, Suvi Sorsa, Mikko Siurala, Riikka Havunen, Siri Tähtinen, Akseli Hemminki, Carl H. June

×

Figure 3

Oncolytic adenovirus (OAd) expressing TNF-α and IL-2, Ad5/3-E2F-D24-TNFa-IRES-IL2 (Ad5/3-OAd-TNFa-IL2), induces robust T cell infiltration of tumors and enhances T cell functions.

Options: View larger image (or click on image) Download as PowerPoint
Oncolytic adenovirus (OAd) expressing TNF-α and IL-2, Ad5/3-E2F-D24-TNFa...
(A) Analysis of CD8+ cell infiltration into the tumor at day 28 by immunohistochemistry (IHC). Representative tumors from the indicated treatment groups are shown. Original magnification, ×20. Scale bars: 100 μm. (B) Quantification of tumor-infiltrating lymphocytes (TILs) at day 28. The number of CD8+ TILs was quantified using Aperio ImageScope software. Number of CD8+ cells was normalized as percentage CD8+ cells in total nucleated cells. Data are representative of 2 experiments from 2 different donors. ***P < 0.001 by 1-way ANOVA with Tukey’s post hoc test. (C) Correlation between intensity of CD8+ TILs and tumor volumes. Number of CD8+ T cells (percentage of total cells) quantified from IHC against tumor sizes at day 28 are plotted. A linear regression line is shown. *P < 0.05. (D) Expression of activation markers on TILs at day 28. T cell activation markers CD95 and CD25 on CD8+ TILs were analyzed by flow cytometry. Data are representative of 2 experiments from 2 different donors. *P < 0.05. (E) Cytokine profile of the bulk tumors at day 14. Cytokines in the supernatant of the homogenate were analyzed by high-sensitivity LUMINEX assay. *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA with Tukey’s post hoc test. (F) Analysis of mesothelin expression by tumors by IHC at day 28. Mesothelin expression by tumor cells was analyzed by IHC (upper panels). Mesothelin-positive area and staining intensity were analyzed with Aperio ImageScope software. Digital masks over the same fields as upper panels are shown in the lower panels. Blue, negative; Yellow, low intensity; Orange, mid intensity; Red, high intensity. Original magnification, ×20. Scale bars: 100 μm. (G) Mesothelin expression by tumors is shown as percentage of mesothelin-positive area. Three tumors (1 from OAd-TNFa-IL2 group and 2 from OAd-TNFa-IL2 + meso-CAR T cell group) are not plotted, as they achieved histological complete remission with no evaluable intact tumor areas. (H) Correlation between mesothelin expression and tumor sizes. Areas of mesothelin positivity (%) are plotted against tumor size at day 28. Linear regression lines are shown. *P < 0.05, **P < 0.01. For vertical scatter plots, bars represent mean and SEM. n = 4–6 each (B–E, and G).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts